Ask AI
ProCE Banner Activity

Roles of TROP-2–Directed ADCs in the Management of HER2-Negative Metastatic Breast Cancer

Clinical Thought

In this commentary, experts address questions about the current and emerging roles and utility of TROP-2–directed ADCs in the management of patients with HER2-negative metastatic breast cancer.

Released: January 12, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This activity is intended for global oncologists and other healthcare professionals who care for patients worldwide with HER2-negative metastatic breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment sequences incorporating TROP-2–directed ADCs to optimize clinical outcomes for patients with HER2-negative MBC

  • Implement evidence-based strategies for monitoring, prophylaxis, and management of adverse events associated with ADCs for patients with HER2-negative MBC

  • Evaluate the clinical implications of emerging evidence on novel approaches using ADCs for treatment of HER2-negative MBC, including in earlier lines of therapy and in combination with immunotherapy

Disclosure

Primary Author

Javier Cortes, MD, PhD: consultant/advisor: Abbvie, AstraZeneca, Bioasis, Biocon, BioInvent, Biontech, Bliss Biopharmaceutical, Boehringer Ingelheim, BridgeBio, Circle Pharma, Clovis Oncology, Daiichi Sankyo, Delcath Systems, Ellipses, Expres2ion Biotechnologies, GEMoaB, Gilead, Hexagon Bio, Hibercell, Jazz, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Reveal Genomics, Roche, Scorpion Therapeutics, Seattle Genetics, Zymeworks; honoraria: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline, Zuellig; researcher (paid to institution): Ariad, AstraZeneca, Baxalta/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, Iqvia, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Roche; individual publicly traded stock/stock options: Leuko; other financial or material support: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline; royalties or patent beneficiary: issued patent: Pharmaceutical Combinations of a PI3K Inhibitor and a Microtubule Destabilizing Agent (WO 2014/199294 A), licensed patent: HER2 as a Predictor of Response to Dual HER2 Blockade in the Absence of Cytotoxic Therapy (US 2019/0338368 A1).

Sara M. Tolaney, MD, MPH: consultant/advisor: Aadi Bio, Artios Pharma, Arvinas, AstraZeneca, Atkis Oncology, Avenzo, Bayer, BeOne, Blueprint Medicines, Bicycle Therapeutics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb/Systimmune, Celcuity, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui USA, Jazz, Johnson & Johnson/Ambrx, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Olema, Pfizer/SeaGen, Reveal Genomics, Samsung Bioepis, Summit, Sumitovant, Tango, Tempus, Zuellig; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, NanoString, Novartis, OncoPep, Pfizer/SeaGen; other financial or material support: Arvians, AstraZeneca, Gilead, Jazz, Lilly, Pfizer, Roche.